Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation
Thrombolysis in Myocardial Infarction Study Group · Brigham and Women's Hospital · +8 more institutions
Abstract
A substantial proportion of patients receiving fibrinolytic therapy for myocardial infarction with ST-segment elevation have inadequate reperfusion or reocclusion of the infarct-related artery, leading to an increased risk of complications and death.
We enrolled 3491 patients, 18 to 75 years of age, who presented within 12 hours after the onset of an ST-elevation myocardial infarction and randomly assigned them to receive clopidogrel (300-mg loading dose, followed by 75 mg once daily) or placebo. Patients received a fibrinolytic agent, aspirin, and when appropriate, heparin (dispensed according to body weight) and were scheduled to undergo angiography 48 to 192 hours after the start of study medication. The primary efficacy end point was a composite of an occluded infarct-related artery (defined by a Thrombolysis in Myocardial Infarction flow grade of 0 or 1) on angiography or death or recurrent myocardial infarction before angiography.
Citation impact
- FWCI
- 101.22
- Percentile
- 100%
- References
- 34
Authors
12- MSMarc S. SabatineCorresponding
Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, Harvard University
- CPChristopher P. Cannon
Brigham and Women's Hospital, Thrombolysis in Myocardial Infarction Study Group, Harvard University
- CMC. Michael Gibson
Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group
- JLJosé Luís López-Sendón
Hospital General Universitario Gregorio Marañón
- GMGilles Montalescot
Sorbonne Université, Fondation pour l’innovation en Cadiométabolisme et Nutrition
Topics & keywords
- Medicine
- Clopidogrel
- Myocardial infarction
- Aspirin
- Cardiology
- Fibrinolytic therapy
- Internal medicine
- ST segment
- Good health and well-being